. Users whose paranoia had worsened over time. 1. Users whose paranoia had worsened over time.
Background Background Psychosis associated with
Psychosis associated with stimulant use is an increasing problem, but stimulant use is an increasing problem, but there is little research evidence aboutthe there is little research evidence aboutthe nature of the problem and its nature of the problem and its management. management.
Aims Aims To critically review the literature
To critically review the literature on stimulant psychosis and sensitisation. on stimulant psychosis and sensitisation.
Method Method Systematic review of studies
Systematic review of studies that have investigated stimulant use and that have investigated stimulant use and psychosis in humans.The main outcome psychosis in humans.The main outcome measures were increases in psychosis with measures were increases in psychosis with stimulant use, and differences between stimulant use, and differences between stimulant users and non-users. stimulant users and non-users.
Results Results Fifty-four studies metthe
Fifty-four studies metthe inclusion criteria. Experimental studies inclusion criteria.Experimental studies show that a single dose of a stimulant drug show that a single dose of a stimulant drug can produce a brief increase in psychosis can produce a brief increase in psychosis ratings (a'response') in 50^70% of ratings (a'response') in 50^70% of participants with schizophrenia and preparticipants with schizophrenia and preexisting acute psychotic symptoms, existing acute psychotic symptoms, unaffected by the presence of unaffected by the presence of antipsychotic medication.Those with antipsychotic medication.Those with schizophrenia who do not have acute schizophrenia who do not have acute psychotic symptoms respond, but less psychotic symptoms respond, but less frequently (30%).There has been little frequently (30%).There has been little research into the longer-term effects of research into the longer-term effects of use. use.
Conclusions Conclusions Compliance with
Compliance with antipsychotic medication by someone with antipsychotic medication by someone with schizophrenia will not prevent a relapse or schizophrenia will not prevent a relapse or worsening of psychotic symptoms if worsening of psychotic symptoms if stimulants are used.Low-dose stimulants are used.Low-dose antipsychotic treatment may be beneficial antipsychotic treatment may be beneficial in stimulant users, to prevent sensitisation. in stimulant users, to prevent sensitisation.
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Stimulants have been used for many cenStimulants have been used for many centuries but only latterly have there been turies but only latterly have there been reports of associated psychosis (Guttmann reports of associated psychosis (Guttmann & Sargant, 1937) , culminating in Connell's & Sargant, 1937) , culminating in Connell's monograph (Connell, 1958) , which remonograph (Connell, 1958) , which reviewed cases of 'stimulant' psychosis that viewed cases of 'stimulant' psychosis that resolved rapidly. In Japan, where there resolved rapidly. In Japan, where there was an epidemic of injected amphetamine was an epidemic of injected amphetamine use, the duration of psychosis appeared to use, the duration of psychosis appeared to be prolonged and chronic (Koyama be prolonged and chronic (Koyama et al et al, , 1991) . The theory was proposed that re-1991). The theory was proposed that repeated low doses of a stimulant lead to peated low doses of a stimulant lead to changes in the central nervous system changes in the central nervous system (CNS) (Ellingwood & Kilbey, 1980) , a (CNS) (Ellingwood & Kilbey, 1980) , a form of 'kindling', which produces a psyform of 'kindling', which produces a psychotic illness similar to schizophrenia. Anichotic illness similar to schizophrenia. Animal experiments seem to support such an mal experiments seem to support such an effect (Post & Kopanda, 1976) . Others effect (Post & Kopanda, 1976) . Others dispute this theory of sensitisation (e.g. dispute this theory of sensitisation (e.g. Brabbins & Poole, 1996) . If sensitisation Brabbins & Poole, 1996) . If sensitisation is occurring, then early treatment and reis occurring, then early treatment and retention of stimulant users in mental health tention of stimulant users in mental health care services would appear to be desirable care services would appear to be desirable to prevent chronic psychoses developing. to prevent chronic psychoses developing. There is a lack of good-quality evidence There is a lack of good-quality evidence as to the effectiveness of this: a recent as to the effectiveness of this: a recent Cochrane review found no relevant trials Cochrane review found no relevant trials (Srisurapanont (Srisurapanont et al et al, 2004) . , 2004). The purpose of this study is to examine The purpose of this study is to examine evidence for the theory of sensitisation. The evidence for the theory of sensitisation. The hypothesis is that stimulant psychoses can hypothesis is that stimulant psychoses can be divided into a 'toxic' type of response be divided into a 'toxic' type of response and a chronic persisting response resulting and a chronic persisting response resulting from longer-term use of stimulants. from longer-term use of stimulants.
METHOD METHOD
We searched for experimental and obserWe searched for experimental and observational studies in humans taking stimuvational studies in humans taking stimulants that investigated or described the lants that investigated or described the development of psychotic symptoms. We development of psychotic symptoms. We did not include case series or cross-sectional did not include case series or cross-sectional studies, as these give little information as to studies, as these give little information as to the direction of effect or changes over time. the direction of effect or changes over time.
We performed electronic searches on We performed electronic searches on Medline, PsycLIT and EMBASE psychiatry Medline, PsycLIT and EMBASE psychiatry from the earliest dates available to 2001, from the earliest dates available to 2001, using the search terms COCAINE, using the search terms COCAINE, CRACK , AMPHETAMINE, METHYL-CRACK, AMPHETAMINE, METHYL-AMPHETAMINE,  METHAMPHETA-AMPHETAMINE,  METHAMPHETA-MINE,  METHAMFETAMINE,  MINE,  METHAMFETAMINE,   D   D--AMPHETAMINE, DEXAMPHETAMINE,  AMPHETAMINE, DEXAMPHETAMINE,  METHYLPHENIDATE,  METHYLPHENIDATE, PSYCHOACTIVE PSYCHOACTIVE DRUGS, CNS STIMULANT DRUGS and DRUGS, CNS STIMULANT DRUGS and DRUG-INDUCED PSYCHOSIS (for stimu-DRUG-INDUCED PSYCHOSIS (for stimulants) lants) and and PSYCHOSIS, PSYCHOSES, PSYCHOSIS, PSYCHOSES, SCHIZOPHRENIA and SCHIZO-SCHIZOPHRENIA and SCHIZO-AFFECTIVE (for psychoses). Where Medi-AFFECTIVE (for psychoses). Where Medical Subject Headings (MeSH) terms were cal Subject Headings (MeSH) terms were available, they were exploded and comavailable, they were exploded and combined. Papers were checked for references bined. Papers were checked for references to other relevant studies. to other relevant studies.
Identifying and evaluating Identifying and evaluating the studies the studies Following the initial searches by C.C., all Following the initial searches by C.C., all experimental case-control and longitudinal experimental case-control and longitudinal studies were independently appraised by studies were independently appraised by C.C. and N.B. Any disagreements on C.C. and N.B. Any disagreements on whether a study should be included were whether a study should be included were resolved by reference to the criteria. Three resolved by reference to the criteria. Three methodologically distinct types of studies methodologically distinct types of studies were identified, which were reviewed were identified, which were reviewed separately. Studies were included if they separately. Studies were included if they met the following criteria. met the following criteria. 
Experimental studies Experimental studies

Longitudinal studies Longitudinal studies
Studies were included if: Studies were included if:
(a) (a) a cohort of substance users with or a cohort of substance users with or without psychosis, defined by operawithout psychosis, defined by operational criteria, was followed up for a tional criteria, was followed up for a defined period; and defined period; and (b) (b) stimulant users were identified and stimulant users were identified and differentiated from other substance differentiated from other substance users in the report. users in the report.
(a) (a) individuals using stimulants with individuals using stimulants with psychosis were compared with those psychosis were compared with those using stimulants with no psychosis; or using stimulants with no psychosis; or (b) (b) individuals with psychosis using stimuindividuals with psychosis using stimulants were compared with control lants were compared with control individuals with psychosis but with no individuals with psychosis but with no history of drug use; or history of drug use; or (c) (c) individuals using stimulants were individuals using stimulants were compared with individuals using noncompared with individuals using nonstimulant substances; and stimulant substances; and (d) (d) Stimulant users are identified and Stimulant users are identified and differentiated from other substance differentiated from other substance users in the report. users in the report.
RESULTS RESULTS
A total of 84 experimental or observational A total of 84 experimental or observational studies were identified by the search and studies were identified by the search and cross-referencing strategies. Initial agreecross-referencing strategies. Initial agreement on studies meeting the criteria in the ment on studies meeting the criteria in the review was present for 89% of the experireview was present for 89% of the experimental studies, 82% of the longitudinal mental studies, 82% of the longitudinal studies and 75% of the case-control studies and 75% of the case-control studies. After discussion between the studies. After discussion between the raters, it was agreed that 43 studies met raters, it was agreed that 43 studies met the criteria the criteria and were thus included in the and were thus included in the review. review.
Experimental studies Experimental studies
A total of 32 experimental studies were A total of 32 experimental studies were included (Table 1) . Twenty-eight of these included (Table 1) . Twenty-eight of these involved single doses of oral or intravenous involved single doses of oral or intravenous (i.v.) dexamfetamine or methylphenidate (i.v.) dexamfetamine or methylphenidate given to individuals with schizophrenia, given to individuals with schizophrenia, and 9 of these 28 studies included a control and 9 of these 28 studies included a control group. One of the remaining 4 studies group. One of the remaining 4 studies included a heterogeneous group of indiviincluded a heterogeneous group of individuals with psychosis and controls given duals with psychosis and controls given two doses of dexamfetamine orally 48 h two doses of dexamfetamine orally 48 h apart (Strakowski apart (Strakowski et al et al, 1997) . Two studies , 1997). Two studies involved substance users (Cami involved substance users (Cami et al et al, 2000; , 2000; Farren Farren et al et al, 2000) . The final study (Casey , 2000) . The final study (Casey et al et al, 1961) was a randomised controlled , 1961) was a randomised controlled trial of 520 individuals with schizophrenia trial of 520 individuals with schizophrenia in which one group received dexamfetain which one group received dexamfetamine orally for 20 weeks. All studies used mine orally for 20 weeks. All studies used some form of standardised rating scalesome form of standardised rating scalemost commonly the Brief Psychiatric most commonly the Brief Psychiatric Rating Scale (BPRS) -to measure changes Rating Scale (BPRS) -to measure changes resulting from stimulant use. A 'response' resulting from stimulant use. A 'response' was considered to have occurred when was considered to have occurred when changes were measured in the psychosis changes were measured in the psychosis component of the various scales. The component of the various scales. The response to a single dose of stimulant, when response to a single dose of stimulant, when present, was brief, seldom lasting more present, was brief, seldom lasting more than a few hours. than a few hours.
The Strakowski The Strakowski et al et al (1997) study (1997) study looked for a response to repeated doses of looked for a response to repeated doses of stimulants. In the control group there was stimulants. In the control group there was a greater response to the second dose of a greater response to the second dose of dexamfetamine than to the first. Particidexamfetamine than to the first. Participants with pre-existing psychosis showed pants with pre-existing psychosis showed no such enhanced response to a second no such enhanced response to a second dose. dose.
The study by Casey The study by Casey et al et al (1961) (1961) examined additional drug therapy in examined additional drug therapy in patients with schizophrenia, all of whom patients with schizophrenia, all of whom were taking antipsychotic medication were taking antipsychotic medication regularly and had not responded to 200-regularly and had not responded to 200-600 mg of chlorpromazine taken daily for 600 mg of chlorpromazine taken daily for at least 2 months. One arm of the study at least 2 months. One arm of the study examined the addition of dexamfetamine examined the addition of dexamfetamine as an adjunctive treatment for schizoas an adjunctive treatment for schizophrenia. There was no benefit from the phrenia. There was no benefit from the addition of dexamfetamine 60 mg daily addition of dexamfetamine 60 mg daily compared with placebo, with worsencompared with placebo, with worsening of 'hostile belligerency, paranoid ing of 'hostile belligerency, paranoid belligerency and thinking disturbance'. belligerency and thinking disturbance'. For 26 studies it was possible to For 26 studies it was possible to perform a statistical analysis of differences perform a statistical analysis of differences in psychotic response between controls, in psychotic response between controls, those with schizophrenia in remission those with schizophrenia in remission and those with positive symptoms, using and those with positive symptoms, using the definitions provided by the studies to the definitions provided by the studies to determine the presence or absence of determine the presence or absence of positive symptoms. There was a methodpositive symptoms. There was a methodological difference between participants ological difference between participants given i.v. dexamfetamine and those given i.v. dexamfetamine and those given oral dexamfetamine or i.v. methgiven oral dexamfetamine or i.v. methamphetamine (see Table 6 ): the doses of amphetamine (see Table 6 ): the doses of dexamfetamine used intravenously were dexamfetamine used intravenously were lower and fixed, as opposed to being lower and fixed, as opposed to being variedaccording to body weight (dexamfetvariedaccording to body weight (dexamfetamine 20 mg as opposed to 0.5 mg/kg amine 20 mg as opposed to 0.5 mg/kg methylphenidate). methylphenidate).
Across the 26 studies, 51.4% of those Across the 26 studies, 51.4% of those with schizophrenia who had positive sympwith schizophrenia who had positive symptoms ( toms (n n¼149), 28.3% of those with schizo-149), 28.3% of those with schizophrenia in remission ( phrenia in remission (n n¼69) and 10.2% of 69) and 10.2% of controls ( controls (n n¼9) had a temporary increase in 9) had a temporary increase in positive symptoms, usually lasting for only positive symptoms, usually lasting for only a matter of hours. An analysis of the effects a matter of hours. An analysis of the effects of the presence of positive symptoms of the presence of positive symptoms v.
v. ababsence of positive symptoms in participants sence of positive symptoms in participants with schizophrenia found a significant with schizophrenia found a significant difference ( difference (w w 
Longitudinal studies Longitudinal studies
Seven longitudinal studies met the inclusion Seven longitudinal studies met the inclusion criteria ( Table 2) . Studies of this type were criteria ( , 1995) and children with attention-deficit 1995) and children with attention-deficit hyperactivity disorder (Cherland & Fitzhyperactivity disorder (Cherland & Fitzpatrick, 1999) . Two of the 11 adults in patrick, 1999). Two of the 11 adults in the first study developed acute psychotic the first study developed acute psychotic symptoms, as did 9 of the 192 children in symptoms, as did 9 of the 192 children in the latter study. Two follow-up studies of the latter study. Two follow-up studies of cocaine users (Gawin & Kleber, 1986; cocaine users (Gawin & Kleber, 1986; Carroll Carroll et al et al, 1993) reported no case of , 1993) reported no case of chronic psychosis. Sato chronic psychosis. Sato et al et al (1983) studied (1983) studied amphe amphetamine users who had previously tamine users who had previously had had long-lasting psychotic episodes who relong-lasting psychotic episodes who reused a stimulant after long periods of abstiused a stimulant after long periods of abstinence. These individuals were found to nence. These individuals were found to relapse after using a lower dose of ampherelapse after using a lower dose of amphetamine than they had used before first betamine than they had used before first becoming psychotic. In one case the person's coming psychotic. In one case the person's relapse seemingly was due to stress, withrelapse seemingly was due to stress, without drug use. The researchers also conout drug use. The researchers also conducted a small, uncontrolled trial of ducted a small, uncontrolled trial of haloperidol 3 mg daily in eight of these haloperidol 3 mg daily in eight of these individuals, none of whom then relapsed individuals, none of whom then relapsed following subsequent amphetamine use. following subsequent amphetamine use. Iwanami Iwanami et al et al (1994) studied individuals (1994) studied individuals who presented with a psychotic illness in who presented with a psychotic illness in the presence of amphetamine use; they the presence of amphetamine use; they identified a small group whose psychotic identified a small group whose psychotic symptoms persisted for several months symptoms persisted for several months after ceasing amphetamine use who were after ceasing amphetamine use who were being prescribed antipsychotic treatment. being prescribed antipsychotic treatment. This group did not meet criteria for This group did not meet criteria for DSM-III schizophrenia (American Psychi-DSM-III schizophrenia (American Psychiatric Association, 1980) but had definite atric Association, 1980) but had definite psychotic symptoms. psychotic symptoms.
Kwapil (1996) reported a 10-year Kwapil (1996) reported a 10-year follow-up study of substance-using follow-up study of substance-using individuals and controls who scored highly individuals and controls who scored highly on the Chapman Questionnaire 'psychosis on the Chapman Questionnaire 'psychosis proneness' section. This self-report quesproneness' section. This self-report questionnaire is designed to measure symptoms tionnaire is designed to measure symptoms and traits reported to be characteristic of and traits reported to be characteristic of proneness to schizophrenia or psychosis. proneness to schizophrenia or psychosis. The study showed that psychosis was not The study showed that psychosis was not predicted by earlier substance use, but the predicted by earlier substance use, but the small number of stimulant users meant that small number of stimulant users meant that the power of the study was insufficient for a the power of the study was insufficient for a meaningful analysis of any link between meaningful analysis of any link between psychosis and stimulants. psychosis and stimulants.
Case^control studies Case^control studies
Most case-control studies identified by the Most case-control studies identified by the search strategy were excluded because it search strategy were excluded because it 2 0 0 2 0 0 
Non-paranoid users Non-paranoid users
Non-sensitised users Non-sensitised users (7)
Greater duration of cocaine use in sensitised Four studies compared cocaine users Four studies compared cocaine users with psychosis with users with no psychosis with psychosis with users with no psychosis (Table 3 ). Heavier cocaine use was shown (Table 3 ). Heavier cocaine use was shown among participants with psychosis comamong participants with psychosis compared with controls in three studies pared with controls in three studies (Manschreck (Manschreck et al et al, 1988; Brady , 1988; Brady et al et al, , 1991; Bartlett 1991; Bartlett et al et al, 1997) . In two studies , 1997). In two studies it was reported that the psychotic episodes it was reported that the psychotic episodes worsened over time (Brady worsened over time (Brady et al et al, 1991; , 1991; Bartlett Bartlett et al et al, 1997) . Five studies compared , 1997). Five studies compared individuals with schizophrenia or another individuals with schizophrenia or another psychotic illness who had been using stimupsychotic illness who had been using stimulants with matched groups who had not lants with matched groups who had not been using stimulants (Table 4) . These been using stimulants (Table 4) . These studies showed a lower age of onset of studies showed a lower age of onset of psychosis in the stimulant-user group, psychosis in the stimulant-user group, fewer negative symptoms and more parafewer negative symptoms and more paranoid themes. First-rank symptoms were noid themes. First-rank symptoms were noted to be fewer and hallucinatory experinoted to be fewer and hallucinatory experiences more common. Seibyl ences more common. Seibyl et al et al (1993 Seibyl et al et al ( ) (1993 showed that most of the people misusing showed that most of the people misusing drugs in their study had begun their cocaine drugs in their study had begun their cocaine use after psychosis had developed. use after psychosis had developed.
Two studies compared people misusing Two studies compared people misusing stimulants with those misusing other drugs stimulants with those misusing other drugs (Table 5) . Graf (Table 5) . Graf et al et al (1977) showed an (1977) showed an increase in the psychotic profile on the increase in the psychotic profile on the 2 01 2 01 Table 6  Table 6 Change in psychotic ratings per substance used and pre-existing psychosis Change in psychotic ratings per substance used and pre-existing psychosis Minnesota Multiphasic Personality InvenMinnesota Multiphasic Personality Inventory at discharge in people using stimulants tory at discharge in people using stimulants rather than other drugs, and Dalmau rather than other drugs, and Dalmau et al et al (1999) showed a significant difference in (1999) showed a significant difference in the rates of psychosis between patients forthe rates of psychosis between patients formerly using amphetamines and those using merly using amphetamines and those using opiates in a study of residents of a drug opiates in a study of residents of a drug rehabilitation unit. rehabilitation unit.
DISCUSSION DISCUSSION
The studies reviewed here provide useful The studies reviewed here provide useful evidence about the effect of stimulant use evidence about the effect of stimulant use on people with pre-existing psychotic illon people with pre-existing psychotic illness, but more limited evidence about the ness, but more limited evidence about the phenomenon of sensitisation. phenomenon of sensitisation.
The expectation that antipsychotic The expectation that antipsychotic medication might block the action of stimumedication might block the action of stimulants and prevent deterioration in psychotic lants and prevent deterioration in psychotic illnesses on exposure is not borne out by illnesses on exposure is not borne out by these studies. The presence of positive these studies. The presence of positive symptoms of schizophrenia (as distinct symptoms of schizophrenia (as distinct from being in remission) appears to make from being in remission) appears to make an individual more likely to experience a an individual more likely to experience a worsening of psychotic symptoms in worsening of psychotic symptoms in response to a single dose of a stimulant drug. response to a single dose of a stimulant drug.
There is clear evidence from these There is clear evidence from these studies that, irrespective of the individual's studies that, irrespective of the individual's mental state, a large enough dose of a mental state, a large enough dose of a stimulant drug can produce a brief psystimulant drug can produce a brief psychotic reaction, usually lasting only hours chotic reaction, usually lasting only hours and being self-limiting in the majority of and being self-limiting in the majority of individuals. The differences between i.v. individuals. The differences between i.v. dexamfetamine, oral dexamfetamine and dexamfetamine, oral dexamfetamine and i.v. methamphetamine in participants with i.v. methamphetamine in participants with active symptoms are probably due to the active symptoms are probably due to the lower doses used in the i.v. dexamfetamine lower doses used in the i.v. dexamfetamine condition -usually a maximum of 20 mg. condition -usually a maximum of 20 mg. Evidence for sensitisation is found in only Evidence for sensitisation is found in only two studies. Strakowski two studies. Strakowski et al et al (1997 Strakowski et al et al ( ) (1997 showed that when two doses of a stimulant showed that when two doses of a stimulant were given to volunteers free from psychowere given to volunteers free from psychosis, the second dose produced a greater sis, the second dose produced a greater psychotic response as measured by the psychotic response as measured by the BPRS -a 'sensitised' response. Stimulant BPRS -a 'sensitised' response. Stimulant users in the study by Brady users in the study by Brady et al et al (1991) (1991) reported psychotic symptoms occurring reported psychotic symptoms occurring with lower doses over time. with lower doses over time.
The difference between patients who The difference between patients who were substance users in the study by were substance users in the study by Dalmau Dalmau et al et al (1999) , where psychosis rates (1999), where psychosis rates were noted to be greater among in-patients were noted to be greater among in-patients who used cannabis or stimulants rather who used cannabis or stimulants rather than opiates, is interesting. Sensitisation is than opiates, is interesting. Sensitisation is a possible contributing factor, but not the a possible contributing factor, but not the only one. The results might have been cononly one. The results might have been confounded by differences in rates of admission founded by differences in rates of admission to the unit. It is possible, for example, that to the unit. It is possible, for example, that those with opiate problems were admitted those with opiate problems were admitted more frequently for in-patient detoxificamore frequently for in-patient detoxification, whereas stimulant users (in whom tion, whereas stimulant users (in whom the withdrawal syndrome is less severe) the withdrawal syndrome is less severe) might have been given out-patient treatmight have been given out-patient treatment. The proportion presenting with psyment. The proportion presenting with psychosis as in-patients would therefore be chosis as in-patients would therefore be greater for those using stimulants rather greater for those using stimulants rather than opiates. than opiates.
The difficulties of researching the longerThe difficulties of researching the longerterm effects of stimulants are seen in the term effects of stimulants are seen in the two Japanese studies (Sato two Japanese studies (Sato et al et al, 1983; , 1983; Iwamani Iwamani et al et al, 1994) . The widespread use , 1994). The widespread use of high-dose injected methamphetamine of high-dose injected methamphetamine led to hospital admissions of individuals led to hospital admissions of individuals with chronic psychosis that persisted after with chronic psychosis that persisted after substance use had ceased. Many patients substance use had ceased. Many patients in these studies could have been given a in these studies could have been given a DSM-IV diagnosis of schizophrenia or DSM-IV diagnosis of schizophrenia or other psychotic illness (American Psychiother psychotic illness (American Psychiatric Association, 1994) but were classed atric Association, 1994) but were classed as having methamphetamine psychosis. as having methamphetamine psychosis.
The small open-label trial of haloperiThe small open-label trial of haloperidol (Sato dol (Sato et al et al, 1983 ) merits attention, if , 1983) merits attention, if only because of the paucity of other evionly because of the paucity of other evidence and the relationship of its results to dence and the relationship of its results to animal studies. Eight of the cohort of animal studies. Eight of the cohort of stimulant users with chronic psychoses stimulant users with chronic psychoses who had relapsed following stimulant use who had relapsed following stimulant use were prescribed small doses of haloperidol were prescribed small doses of haloperidol (3 mg daily) following recovery and were (3 mg daily) following recovery and were observed for further relapse. These particiobserved for further relapse. These participants did not relapse, even if they returned pants did not relapse, even if they returned to stimulant use; however, participants who to stimulant use; however, participants who were not given haloperidol relapsed into a were not given haloperidol relapsed into a psychotic state lasting days to weeks after psychotic state lasting days to weeks after using stimulants. The results could lead us using stimulants. The results could lead us to postulate that where people are unable to postulate that where people are unable to abstain from stimulant use despite reto abstain from stimulant use despite repeated psychotic episodes, small doses of peated psychotic episodes, small doses of regular antipsychotic medication adminisregular antipsychotic medication administered once the episode has settled might tered once the episode has settled might reduce or prevent sensitisation in the future. reduce or prevent sensitisation in the future.
Human experimental studies investigatHuman experimental studies investigating sensitisation are unlikely because of ing sensitisation are unlikely because of ethical considerations, but a number of anethical considerations, but a number of animal experiments have been carried out. imal experiments have been carried out. Stimulant-induced stereotyped behaviour Stimulant-induced stereotyped behaviour in small mammals and possible hallucinain small mammals and possible hallucinatory experiences in primates have been used tory experiences in primates have been used as a model for schizophrenia in humans. In as a model for schizophrenia in humans. In animals, the response to chronic amphetaanimals, the response to chronic amphetamine use has been divided into two phases. mine use has been divided into two phases. In the 'initiation' phase of these experiIn the 'initiation' phase of these experiments animals are 'sensitised' by small ments animals are 'sensitised' by small regular doses of stimulants, insufficient to regular doses of stimulants, insufficient to cause a 'psychotic' reaction on their own. cause a 'psychotic' reaction on their own. The 'expression' phase occurs if the animals The 'expression' phase occurs if the animals are either stressed or given a single dose of are either stressed or given a single dose of a stimulant. In the first phase, sensitisaa stimulant. In the first phase, sensitisation has been shown to be blocked by tion has been shown to be blocked by antipsychotic drugs, whereas the psychotic antipsychotic drugs, whereas the psychotic reaction in the expression phase is not reaction in the expression phase is not always blocked (Lieberman always blocked (Lieberman et al et al, 1990) . , 1990). Castner & Goldman-Rakic (1999) investiCastner & Goldman-Rakic (1999) investigated rhesus monkeys, which were given gated rhesus monkeys, which were given intermittent, escalating low doses of intermittent, escalating low doses of amphetamine over a 12-week period, amphetamine over a 12-week period, followed by an acute challenge with lowfollowed by an acute challenge with lowdose amphetamine (0.4-0.46 mg/kg). dose amphetamine (0.4-0.46 mg/kg). Enhanced responses (hallucinatory-like Enhanced responses (hallucinatory-like behaviours, static posturing and motor behaviours, static posturing and motor stereotypies) were noted in response to a stereotypies) were noted in response to a low-dose amphetamine challenge 5 days low-dose amphetamine challenge 5 days after withdrawal and up to 28 months later. after withdrawal and up to 28 months later. The monkeys also showed an increase in The monkeys also showed an increase in responses 'independent of stimuli', possibly responses 'independent of stimuli', possibly indicating hallucinations, in the absence of indicating hallucinations, in the absence of additional drug challenges. Antipsychotic additional drug challenges. Antipsychotic drugs were not used. drugs were not used.
Meng Meng et al et al (1998) performed a similar (1998) performed a similar experiment on rats, but also pre-treated experiment on rats, but also pre-treated one group of rats with high-dose haloone group of rats with high-dose haloperidol (0.5 mg/kg) or clozapine (20 mg/ peridol (0.5 mg/kg) or clozapine (20 mg/ kg), withholding the 'sensitising' phase of kg), withholding the 'sensitising' phase of amphetamines. This group showed an amphetamines. This group showed an enhanced response to amphetamine chalenhanced response to amphetamine challenge in a similar way to those sensitised lenge in a similar way to those sensitised with amphetamines. Rats that had been with amphetamines. Rats that had been given low-dose antipsychotic treatment given low-dose antipsychotic treatment (haloperidol 0.1 mg/kg or clozapine 4 mg/ (haloperidol 0.1 mg/kg or clozapine 4 mg/ kg) alongside regular amphetamine adminkg) alongside regular amphetamine administration did not show an enhanced effect, istration did not show an enhanced effect, suggesting that they were not sensitised, in suggesting that they were not sensitised, in a similar way to the humans in the study a similar way to the humans in the study by Sato by Sato et al et al (1983) . The sensitisation (1983) . The sensitisation following high-dose antipsychotic treatfollowing high-dose antipsychotic treatment is presumably related to dopamine ment is presumably related to dopamine receptor upregulation, which occurs in receptor upregulation, which occurs in these circumstances, increasing the vulnerthese circumstances, increasing the vulnerability of the brain to stimulants once the ability of the brain to stimulants once the antipsychotic treatment is stopped. antipsychotic treatment is stopped.
Evidence against sensitisation occurring Evidence against sensitisation occurring can be found. Seibyl can be found. Seibyl et al et al (1993 Seibyl et al et al ( ) noted that (1993 noted that for the majority of participants stimulant for the majority of participants stimulant use began after the onset of psychotic illuse began after the onset of psychotic illness, again weakening the case for a causaness, again weakening the case for a causative role for stimulants. We identified only tive role for stimulants. We identified only two studies that looked specifically at the two studies that looked specifically at the therapeutic use of methylphenidate and therapeutic use of methylphenidate and psychosis (Pawluck psychosis (Pawluck et al et al, 1995; Cherland , 1995; Cherland & Fitzpatrick, 1999) , but many studies & Fitzpatrick, 1999), but many studies have established the safety of this agent, have established the safety of this agent, although not specifically reporting or exalthough not specifically reporting or examining for psychosis (e.g. Efron amining for psychosis (e.g. Efron et al et al, , 1997) . Illicit use of methylphenidate, how-1997). Illicit use of methylphenidate, however, tends to follow a different pattern, ever, tends to follow a different pattern, with binges and escalation of dose with binges and escalation of dose occurring. occurring.
The lack of evidence in this area of psyThe lack of evidence in this area of psychiatry causes problems for clinicians who chiatry causes problems for clinicians who 2 0 2 2 0 2 must plan management without a solid evimust plan management without a solid evidence base for a group of patients whose dence base for a group of patients whose management is challenging. Using the data management is challenging. Using the data from these studies, we can say clearly that from these studies, we can say clearly that use of stimulants leads to a brief psychotic use of stimulants leads to a brief psychotic reaction, usually only hours in length, that reaction, usually only hours in length, that is more pronounced in people who already is more pronounced in people who already have active symptoms of psychosis and is have active symptoms of psychosis and is seemingly unaffected by antipsychotic seemingly unaffected by antipsychotic medication. With regard to the hypothesis medication. With regard to the hypothesis that stimulant use can produce chronic that stimulant use can produce chronic psychosis, supportive evidence is present psychosis, supportive evidence is present in studies of humans but is of lower quality, in studies of humans but is of lower quality, although supported by experimental animal although supported by experimental animal studies. studies.
In the absence of better evidence, treatIn the absence of better evidence, treatment of stimulant-induced psychosis should ment of stimulant-induced psychosis should probably involve efforts to encourage probably involve efforts to encourage abstinence from stimulants and medication abstinence from stimulants and medication with antipsychotic drugs until the acute with antipsychotic drugs until the acute symptoms settle. This should be followed symptoms settle. This should be followed by regular low doses of antipsychotics in by regular low doses of antipsychotics in those who have experienced more than those who have experienced more than one episode of psychosis. Given that the one episode of psychosis. Given that the evidence (however poor) points to sensitisaevidence (however poor) points to sensitisation occurring, it is important that people tion occurring, it is important that people using stimulants should be assertively using stimulants should be assertively managed in an attempt to prevent longmanaged in an attempt to prevent longterm chronic psychosis. term chronic psychosis. Response to apomorphine, amphetamine and neuroleptics in to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. schizophrenic subjects. Psychopharmacology Psychopharmacology, , 67 67, 31^38. , 31^38.
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LIMITATIONS LIMITATIONS
& & There is little evidence for the effects of long-term stimulant use, and because of There is little evidence for the effects of long-term stimulant use, and because of the methodological difficulties, it is poor in quality or derived from animal the methodological difficulties, it is poor in quality or derived from animal experiments. experiments. The effects of other psychoactive drugs confound many of the studies of this subject, which were therefore excluded from the review. subject, which were therefore excluded from the review. The only treatment study available is a small open trial.
